Novartis says GOLD recommends broad use of dual bronchodilators to treat COPD
Novartis welcomes the publication of the Global Initiative for Chronic Obstructive Lung Disease, or GOLD, 2017 report. For the first time, GOLD has recommended the first-line use of dual bronchodilators, such as Ultibro Breezhaler 110/50 mcg, in the treatment of the majority of symptomatic chronic obstructive pulmonary disease, or COPD, patients, regardless of their exacerbation risk. The GOLD 2017 report is a tool to help health care professionals worldwide implement effective COPD management programs. Significantly, the use of inhaled steroid-containing combination therapies is now only recommended in a minority of patients, following dual bronchodilator treatment.